Target intelligence / Profile preview

novel transcript, antisense to RREB1

Molecular classification: Other, non-coding RNA, antisense transcript

Overview

novel transcript, antisense to RREB1" (ENSG00000309364) is annotated as a non-coding RNA transcript overlapping the RREB1 gene in an antisense orientation. There is currently no evidence in the biomedical literature that this transcript encodes a protein, functions as a therapeutic target, or is involved in disease mechanisms. The primary gene, RREB1, is a well-characterized zinc finger transcription factor involved in Ras signaling, cancer, development, and other biological processes[1][3]. However, the antisense transcript itself is of unknown function and is not classified as a validated molecular target.

Other names: ENSG00000309364

Beyond the preview

Go deeper on novel transcript, antisense to RREB1.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Drug pipeline

Explore the programs pursuing this target and their development progress.

Drug candidates
Developers
Development stage

Clinical trials

Follow the clinical studies evaluating therapies directed at this target.

Trial design
Status
Readouts

Competitive landscape

Compare approaches across drug candidates, modalities, and indications.

Programs
Modalities
Indications

Literature & evidence

Investigate the research and source evidence behind target biology and development.

Publications
Sources
Analysis

Patents

Explore patent activity around therapies and technologies addressing this target.

Patents
Assignees
Technologies

Research & analysis

Connect target biology, drug development, and emerging evidence in your research.

Biology
Development news
Analysis

Bring the full picture into focus.

See how Gosset can support your research on novel transcript, antisense to RREB1.

Explore the full profile